ClinicalTrials.gg
CompletedNCT05751642Updated Nov 27, 2024

Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants

A Phase 1 interventional study of ALXN1920 and Placebo in Healthy Participants, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 2 sites in New Zealand. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single ascending doses (SADs) of ALXN1920 subcutaneous (SC) and of a single dose of ALXN1920 intravenous (IV) in healthy adult participants.

Read the detailed description

This is a first-in-human study in healthy adult participants.

Eligible participants will be randomly assigned in a 3:1 (ALXN1920:Placebo) ratio in each of the treatment cohorts. The first 2 participants randomized to each cohort will be dosed as a sentinel pair, with 1 participant on active treatment and 1 participant on placebo. At the discretion of the Investigator, up to 3 more participants will be added at least 48 hours after the dosing of the sentinel pair, followed by dosing of the remaining participants in the cohort no earlier than 72 hours after sentinel pair dosing.

The study will comprise:

A Screening Period of up to 28 days; A Dosing Period (single dose through to Follow-up Visit) of approximately 28 days; A Final Follow-up period and end of study Visit is planned on Day 29.

Each participant will be involved in the study for approximately 56 days.

02

Conditions studied

  • Healthy Participants

Keywords

  • First-in-human
  • Single ascending dose
  • Sentinel dosing
  • ALXN1920
  • Safety
  • Pharmacokinetics
  • Pharmacodynamics
  • Japanese Descent
03

In context

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.

Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.

First submitted after Alexion Pharmaceuticals, Inc. became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants
  • within 18.0 to 32.0 kg/m\^2 (inclusive), with a minimum body weight of 50.0 kg.
  • Female participants of and male participants must follow protocol-specified guidance.
  • For Cohort 6, participants of Japanese descent, defined as having both parents and 4 grandparents who are ethnically Japanese.

Exclusion criteria

Exclusion Criteria:

  • Significant history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders.
  • History of significant allergic reaction.
  • History of any Neisseria infection
  • Active systemic bacterial, viral, or fungal infection.
  • Participants who at Day -1 are either testing positive for coronavirus disease 2019 (COVID-19), or have not had at least 4 weeks elapse of recovery time (a negative test), or are experiencing long-term COVID-19-related sequelae.
  • Any major surgery within 8 weeks of Screening.
  • Known or suspected history of drug or alcohol abuse.
  • Current tobacco users or smokers.
  • Positive (HIV) infection, or viral infection.
  • Female participant who are pregnant, breastfeeding, or intending to conceive during the course of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive a single dose of ALXN1920.

    Biological: ALXN1920

  • Experimental
    Cohort 2

    Participants will receive a single dose of ALXN1920.

    Biological: ALXN1920

  • Experimental
    Cohort 3

    Participants will receive a single dose of ALXN1920.

    Biological: ALXN1920

  • Experimental
    Cohort 4

    Participants will receive a single dose of ALXN1920.

    Biological: ALXN1920

  • Experimental
    Cohort 5

    Participants will receive a single dose of ALXN1920.

    Biological: ALXN1920

  • Experimental
    Cohort 6: Japanese Cohort

    Japanese participants will receive a single dose of ALXN1920.

    Biological: ALXN1920

  • Placebo comparator
    Pooled Placebo

    Participants will receive Placebo.

    Biological: Placebo

Interventions

  • BiologicalALXN1920

    Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection.

  • BiologicalPlacebo

    Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion.

  • BiologicalALXN1920

    Participants will receive a single dose of ALXN1920 by SC infusion.

  • BiologicalALXN1920

    Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse events (AEs)

    To assess the safety and tolerability of single ascending doses of ALXN1920.

    Time frame: Up to End of study visit (Day 29)

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    To assess the Cmax of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  2. Time to maximum observed concentration (tmax)

    To assess the tmax of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  3. Area under the concentration-time curve from time 0 (dosing) to the last quantifiable concentration (AUC0-t)

    To assess the AUC0-t of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  4. Area under the concentration-time curve from time 0 (dosing) to time infinity (AUCinf)

    To assess the AUCinf of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  5. Terminal elimination half-life (t½)

    To assess the t½ of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  6. Terminal-phase elimination rate constant (λz)

    To assess the λz of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  7. Total body clearance (CL)

    To assess the CL of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  8. Apparent clearance (CL/F)

    To assess the CL/F of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  9. Volume of distribution (Vd)

    To assess the Vd of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  10. Apparent volume of distribution (Vd/F)

    To assess the Vd/F of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 6 and 12 hours post-dose), post-dose on Day 2, 3, 4, 5, 6, 8, 15, 22, and 29

  11. Renal clearance (CLR)

    To assess the CLR of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 through Day 5 (Pre-dose and up to 96 hours post-dose)

  12. Amount of unchanged drug excreted in urine (Ae)

    To assess the Ae of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 through Day 5 (Pre-dose and up to 96 hours post-dose)

  13. Fraction of dose excreted in urine (fe)

    To assess the fe of ALXN1920 following single ascending doses of ALXN1920.

    Time frame: Day 1 through Day 5 (Pre-dose and up to 96 hours post-dose)

  14. Change in complement alternative pathway (CAP) activity

    To explore the Pharmacodynamic (PD) effects of single ascending doses of ALXN1920. CAP activity will be assessed using the CAP hemolytic assay.

    Time frame: Day 1 (Pre-dose, 0.5, 1 and 2 hours post-dose), post-dose on Day 2, 3, 4, 5, 8, 15, 22, and 29

  15. Change in factor H

    To explore the PD effects of single ascending doses of ALXN1920. Change in factor H will be assessed using the factor H assay.

    Time frame: Day 1 (Pre-dose, 0.5, 1 and 2 hours post-dose), post-dose on Day 2, 3, 4, 5, 8, 15, 22, and 29

  16. Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1920

    To assess the immunogenicity to ALXN1920.

    Time frame: Day 1 pre-dose and Day 29 post-dose

  17. Geometric Mean Ratio (GMR) of Area Under the Curve (AUC) Values of Subcutaneous (SC) Versus Intravenous (IV) Serum Concentration of ALXN1920

    To assess the absolute bioavailability of ALXN1920 SC.

    Time frame: Day 29 post-dose

07

Study locations

2 sites
  • Clinical Trial Site
    Grafton, Auckland 1010, New Zealand
  • Research Site
    Christchurch, 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Dec 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 2, 2023
StartActual
Apr 19, 2023
Primary completionActual
Dec 4, 2023
CompletionActual
Dec 4, 2023
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05751642
Responsible party
Sponsor
First posted
Mar 2, 2023
Start date
Apr 19, 2023
Primary completion
Dec 4, 2023
Completion
Dec 4, 2023
Last update
Nov 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion